CN BIO INNOVATIONS LIMITED
Get an alert when CN BIO INNOVATIONS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£6.8m
-31.4% vs 2024
Net assets
£8.2m
-34.6% first positive since 2023
Employees
47
-4.1% vs 2024
Profit before tax
-£4.3m
+31.2% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
As these stakeholders and future receipts are not controlled by the Company, this represents a material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern
-
Going-concern uncertainty disclosed
Net assets
5-year trend · vs Technology median
Accounts
5-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|
| Turnover | £1,672,453 | £2,131,336 | £3,425,098 | £3,467,383 | £5,397,909 | +55.7% | |
| Operating profit | -£3,008,021 | -£3,931,799 | -£5,094,969 | -£6,142,752 | -£4,496,405 | +26.8% | |
| Profit before tax | -£3,013,297 | -£4,120,789 | -£5,521,172 | -£6,242,817 | -£4,293,483 | +31.2% | |
| Net profit | -£3,013,297 | -£4,120,789 | -£5,521,172 | -£6,332,622 | -£4,347,844 | +31.3% | |
| Cash | £248,672 | £3,399,215 | £650,669 | £9,961,406 | £6,828,728 | -31.4% | |
| Total assets less current liabilities | £2,020,404 | £5,902,343 | -£6,555,144 | £12,578,692 | £8,627,130 | -31.4% | |
| Net assets | £932,004 | -£1,493,950 | -£6,584,498 | £12,552,925 | £8,205,081 | -34.6% | |
| Equity | £932,004 | -£1,493,950 | — | £12,552,925 | £8,205,081 | -34.6% | |
| Average employees | 36 | 45 | 43 | 49 | 47 | -4.1% | |
| Wages | — | — | £3,047,161 | £3,273,289 | £3,423,719 | +4.6% | |
| Directors' remuneration | — | — | £190,806 | £233,200 | £283,800 | +21.7% | |
| Directors' pension contributions | — | — | £11,400 | £13,200 | — | — | |
| Highest paid director | — | — | £190,806 | £233,200 | £283,800 | +21.7% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Operating margin | -179.9% | -184.5% | -148.8% | -177.2% | -83.3% | |
| Net margin | -180.2% | -193.3% | -161.2% | -182.6% | -80.5% | |
| Return on capital employed | -148.9% | -66.6% | — | -48.8% | -52.1% | |
| Gearing (liabilities / total assets) | 57.4% | 126.3% | 253.4% | 9.2% | 19.8% | |
| Current ratio | — | — | 0.29x | 10.16x | 5.67x | |
| Interest cover | — | -20.80x | -10.75x | -17.84x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- CN BIO INNOVATIONS LIMITED 2014-01-23 → present
- ZYOXEL LIMITED 2008-10-16 → 2014-01-23
- M&R 1070 LIMITED 2008-02-28 → 2008-10-16
Audit & accounting basis
- Accounting basis
- FRS 102 §1A
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“As these stakeholders and future receipts are not controlled by the Company, this represents a material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern”
Group structure
- CN BIO INNOVATIONS LIMITED · parent
- 28 North Discovery Limited 100%
Significant events
- “An impairment of £85,192 was made in the year against patent costs that were considered not to be recoverable against the future sale of related products.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BROOKS, Paul Robert, Dr | Director | 2023-01-01 | Dec 1968 | British |
| CHONG, Hok Hei Charles, Mr. | Director | 2011-08-31 | Dec 1958 | British |
| CHOW, Ka Lok Kevin, Dr | Director | 2025-03-31 | Jan 1978 | Hong Konger |
| COLEMAN, Maureen Sheila Helen | Director | 2010-04-27 | Apr 1953 | British |
| SCALES, Michael David Courtney | Director | 2018-12-20 | Jan 1952 | British |
| TONG, Fung Cheuk, Dr | Director | 2023-01-01 | May 1959 | Hong Konger |
| TSE, Andy Po Shing | Director | 2009-07-10 | Jul 1966 | Chinese |
| YIN, Wang | Director | 2024-06-25 | May 1986 | Chinese |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LIM, Zickie | Secretary | 2008-02-28 | 2008-11-17 |
| M&R SECRETARIAL SERVICES LIMITED | Corporate Secretary | 2008-11-17 | 2015-03-26 |
| BRINDLE, Stephen | Director | 2010-07-02 | 2016-03-29 |
| CUI, Zhanfeng, Professor | Director | 2008-11-17 | 2015-01-21 |
| D'ABBADIE, Marc Francois | Director | 2009-07-10 | 2009-09-18 |
| HART, Timothy David, Dr | Director | 2008-11-17 | 2012-10-18 |
| HUGHES, David James, Dr | Director | 2015-07-27 | 2022-11-16 |
| PICKTHORN, Tom | Director | 2008-02-28 | 2008-11-17 |
| SCEATS, Emma Louise, Dr | Director | 2014-06-30 | 2018-07-18 |
| SU, Yuexing | Director | 2024-06-04 | 2025-03-31 |
| XIONG, Anqi | Director | 2019-09-25 | 2024-06-25 |
| YIP, Kwok Keong | Director | 2009-07-10 | 2011-08-31 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 144 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-16 | AA | accounts | Accounts with accounts type full | |
| 2026-02-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-24 | CH01 | officers | Change person director company with change date | |
| 2025-11-24 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-08-19 | AA | accounts | Accounts with accounts type full | |
| 2025-04-02 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-02 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-05 | AA | accounts | Accounts with accounts type full | |
| 2024-11-15 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-08-29 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2024-08-09 | SH01 | capital | Capital allotment shares | |
| 2024-07-13 | RP04AP01 | officers | Second filing of director appointment with name |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 11
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.